KOSDAQBiotech & Pharma007370

Jin Yang Pharmaceutical

₩3,385▲ 1.35%2026-11-18 close
Market Cap
₩47.8B
Turnover
₩67,329,738
Volume
20K
Shares out.
14.1M
PER
1.7×
PBR
0.3×
EPS
₩1,981
Dividend Yield
4.45%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩150 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Grows, Profit Swings at JIN Yang Pharmaceutical

JIN Yang Pharmaceutical's revenue rose for three straight years through 2025, but operating profit fell sharply in 2025, and whether operating profit stays positive through 2026 is the key point to watch.

  1. 1

    Revenue reached KRW 120.7 billion in 2025, rising for three consecutive years from 2023, but growth slowed to 6.5% that year.

  2. 2

    Operating profit fell to KRW 2.53 billion in 2025, down 78.4% year on year, and the operating margin dropped to 2.1%. The company cited a temporary rise in selling and administrative expenses as the main cause.

  3. 3

    Quarterly operating profit was positive in each quarter from the first quarter of 2026 through the third quarter, although the third-quarter figure fell 41.3% from the prior quarter.

  4. 4

    Of the KRW 25 billion in owner net income over the last four quarters, the fourth quarter of 2025 accounted for most of the total, so quarterly swings are large.

  5. 5

    Revenue centers on ethical prescription drugs (ETC) sold through hospitals and clinics, which accounted for 77.8% of sales in 2023, with the antiplatelet drug Crivix at the core.

02

Business structure

JIN Yang Pharmaceutical was founded in 1971 and listed on KOSDAQ in July 2000, and its business centers on ethical prescription drugs (ETC) sold through hospitals and clinics.

According to a June 2024 Valuefinder report, the 2023 sales mix was 77.8% ETC, 19.2% contract biopharmaceutical manufacturing (CMO), and 3.0% over-the-counter (OTC) products. The largest ETC category is circulatory drugs, and one press report put 2024 circulatory sales at KRW 35.4 billion, or 31.2% of the total.

The flagship product is the antiplatelet drug Crivix, a generic of Sanofi's Plavix with clopidogrel as the active ingredient. The key gastrointestinal product is the reflux treatment Esol, and gastrointestinal sales rose from KRW 6.5 billion in 2020 to KRW 11.7 billion in 2023.

Acecol is the growth product in the central nervous system category, and one report said metabolic drug sales more than doubled over four years. The CMO business relies on the cGMP production facility at the Wonju plant, which was completed in 2015.

Valuefinder forecast CMO sales would grow from KRW 5.8 billion in 2019 to KRW 25 billion in 2024, but that is a forecast, not a reported result. Industry commentary credited 2023 profit recovery to better CMO sales, wider sales channels, and ETC growth.

In contract biopharma manufacturing, the gap with the large CMO player Samsung Biologics is wide in plant scale and customer base.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩29.2B-₩900M−3.2%
2025Q4₩30.3B-₩2.9B−9.4%
2026Q1₩32.4B₩3.4B10.4%
2026Q2₩32.6B₩4.2B12.9%
2026Q3₩32.6B₩2.5B7.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩76.3B₩11.1B₩12.3B14.6%15.9%47.5%
2023₩94.1B₩9.1B₩12.7B9.7%14.1%33.8%
2024₩113.3B₩11.7B₩29.7B10.3%24.8%89.8%
2025₩120.7B₩2.5B₩22.3B2.1%13.9%67.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

In the annual results, revenue rose from KRW 76.3 billion in 2022 to KRW 94.1 billion in 2023 (up 23.4% year on year), KRW 113.3 billion in 2024 (up 20.4%), and KRW 120.7 billion in 2025 (up 6.5%), rising for three consecutive years from 2023.

Operating profit fell from KRW 11.1 billion in 2022 to KRW 9.09 billion in 2023 (down 18.4%), then recovered to KRW 11.7 billion in 2024 (up 28.9%). Operating profit fell to KRW 2.53 billion in 2025, down 78.4%, and the operating margin of 2.1% was the lowest of the 2022 to 2025 period.

A press report on the 2025 results said the company attributed the drop to a temporary rise in selling and administrative expenses. Owner net income went from KRW 12.3 billion in 2022 to KRW 12.7 billion in 2023 (up 2.8%) and KRW 29.7 billion in 2024 (up 134.6%), before falling to KRW 22.3 billion in 2025 (down 24.9%).

For 2024, the company explained the profit gain partly by a revaluation gain on an investment property acquired earlier, which is non-operating in nature and should be separated from core earnings.

Operating cash flow fell to KRW 1.46 billion in 2025 from KRW 12.8 billion in 2024, while the debt ratio declined from 89.8% in 2024 to 67.5% in 2025.

Quarterly, operating losses in the third and fourth quarters of 2025 turned into operating profit of KRW 3.37 billion in the first quarter of 2026, followed by KRW 4.22 billion in the second quarter and KRW 2.48 billion in the third quarter. Third-quarter 2026 revenue was KRW 32.6 billion, up 11.5% year on year.

Owner net income peaked at KRW 19.3 billion in the fourth quarter of 2025, then fell in each of the three quarters from the first quarter of 2026 to KRW 1.18 billion in the third quarter.

The fourth quarter of 2025 showed an operating loss of KRW 2.85 billion but owner net income of KRW 19.3 billion, which suggests non-operating or one-off items played a large role, and their details should be checked in the periodic report.

Because the fourth quarter of 2025 accounts for most of the KRW 25 billion owner net income over the last four quarters, recent quarterly profit alone is not a clean read of core earnings power.

05

Industry analysis

The domestic ethical drug market is strongly shaped by hospital and clinic prescription volumes and the national health insurance drug pricing system.

Treatments for chronic conditions such as hypertension, high cholesterol and diabetes see steady prescription demand as the population ages, which is a supportive backdrop for JIN Yang Pharmaceutical's focus on circulatory and metabolic products.

Off-patent ingredients such as antiplatelet agents face intense price competition among generics, so holding market share requires sales strength and prescribing channel management. One press report said the company is strengthening its sales force to expand local market share in the circulatory segment.

The contract biopharmaceutical manufacturing market depends on long-term contracts with large clients and plant utilization, so mid-sized CMO businesses can see wide earnings swings depending on how quickly they win clients.

Listed pharma companies on KOSDAQ increasingly differentiate through improved new drugs and combination products, and a 2025 press report said JIN Yang is running a Phase 3 trial of its diabetes drug JY303 and has filed for approval of JY304, a generic for peptic ulcer treatment.

Compared with large listed companies focused on novel drug development, such as Hanmi Pharm and Yuhan, JIN Yang's structure leans more on ethical drug sales and production capacity. A direct comparison with Samsung Biologics, a leading CMO, is difficult because the scale and customer structure differ widely.

The industry therefore combines supportive demand from population aging with constraints from drug pricing regulation and generic price competition.

06

Outlook

The most recent quarterly markers are third-quarter 2026 revenue of KRW 32.6 billion, up 11.5% year on year, and operating profit of KRW 2.48 billion.

Operating profit has stayed positive so far in 2026, so the key question for coming quarters is whether the cost structure has normalized after selling and administrative expenses rose at the end of 2025.

The company is reported to be running a Phase 3 trial of a combination diabetes drug pairing dapagliflozin with glimepiride. A 2024 press report said the company targeted KRW 4 billion in sales for this product in 2026, but that target dates from 2024 and is hard to treat as a current plan.

JY303, a diabetes drug, is in Phase 3, and JY304, a generic peptic ulcer drug, has completed its approval filing, according to a 2025 report. One report cited a 2024 forecast that CMO sales would reach KRW 25 billion in 2024, which was an estimate rather than a reported figure.

No formal company guidance has been confirmed, so the quarterly disclosure trend is the most direct reference point. The 2026 annual business report will summarize full-year 2026 results and pipeline progress, making it the baseline for future expectations.

On profitability, the test is how far the operating margin recovers from 2.1% in 2025. Also worth watching is whether owner net income stops declining after three consecutive quarterly drops.

07

Valuation

PER
1.7×
PBR
0.3×
ROE
17.2%
EPS
₩1,981
BPS
₩13,397
Dividend per share
₩150

Valuation is hard to read from multiples alone when earnings are swinging, so asset-based comparisons are used alongside them. The sharp fall in 2025 operating profit and the possibility that one-off items drove the fourth quarter of 2025 owner net income mean earnings over the last four quarters vary widely.

Equity attributable to owners was KRW 159.9 billion at the end of 2025, the same as total equity. Because market capitalization sits well below total equity, the price-to-book ratio is at a low level.

In June 2024, the independent research firm Valuefinder said business segments and earnings growth were not fully reflected in the share price, but that assessment predates the 2025 earnings decline.

Compared with large biopharma companies, the business structure and earnings scale differ, so multiple comparisons carry limited meaning. The low price-to-book level can be read in different ways, depending on how much weight is given to earnings volatility and product concentration.

Dividend yield depends on the company's dividend policy, so whether dividends can be sustained in a year when earnings are volatile is a point to check.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Sales growth continued for three years

Revenue rose for three consecutive years from 2023, reaching KRW 120.7 billion in 2025. Third-quarter 2026 revenue was KRW 32.6 billion, up 11.5% year on year. Because the sales base is spread across circulatory, gastrointestinal and central nervous system products, dependence on any single product is partly reduced.

Quarterly operating profit stayed positive in 2026

Operating profit was KRW 3.37 billion in the first quarter of 2026, KRW 4.22 billion in the second and KRW 2.48 billion in the third, all positive. That marks a departure from the operating losses seen in the third and fourth quarters of 2025.

Second-quarter operating profit rose 25.1% from the prior quarter, which points to possibly lighter cost pressure.

Improved-drug pipeline in progress

A 2025 report said the diabetes drug JY303 is in Phase 3 and that JY304, a generic peptic ulcer drug, has completed its approval filing. A combination product pairing dapagliflozin with glimepiride is also reported to be in Phase 3. If these products reach sales, the ETC-focused structure could broaden.

09

Bear factors

Operating profit collapsed in 2025

Operating profit fell to KRW 2.53 billion in 2025, down 78.4%, and the operating margin was 2.1%. The company pointed to a temporary rise in selling and administrative expenses. Operating cash flow also dropped to KRW 1.46 billion from KRW 12.8 billion in 2024.

Concern over reliance on one-off items

Owner net income of KRW 19.3 billion in the fourth quarter of 2025 makes up most of the KRW 25 billion total for the last four quarters. Because that quarter had an operating loss of KRW 2.85 billion, the share of non-operating items needs to be confirmed in the periodic report. Owner net income declined in each quarter of 2026 so far.

Generic competition in the core product

The core product Crivix is a clopidogrel generic, so it faces price competition from other products with the same ingredient. Circulatory drugs account for about 31% of sales, which leaves the revenue base concentrated in one category. The CMO growth figures are 2024 estimates and may differ from actual results.

10

Risk factors

Product concentration and competition

If concentration in circulatory products and generic price competition persist, revenue growth could slow further. Sales growth had already dropped to 6.5% in 2025. If new product launches are delayed, the company could face a gap in its growth drivers.

Earnings volatility and one-off items

The operating margin fell to 2.1% in 2025, and quarterly operating profit was in the red in the third and fourth quarters of 2025. Some periods show large non-operating effects on owner net income, which makes earnings quality harder to judge. Until the periodic report details one-off items, it is hard to pin down core earnings.

Cash flow and financial burden

Operating cash flow fell sharply to KRW 1.46 billion in 2025 from KRW 12.8 billion in 2024. The debt ratio declined from 89.8% in 2024 to 67.5% in 2025, but total liabilities remain at KRW 108 billion.

Working capital movements can weigh heavily on cash flow, so the cash flow statement in the next periodic report is worth checking.

11

What to watch next

  1. Early February 2027 (estimated from last year's timing)

    Preliminary 2026 full-year results. This is the first check on whether operating profit recovers after the sharp 2025 decline.

  2. By March 31, 2027

    Filing of the 2026 annual business report, due within 90 days of fiscal year-end. It will show the annual operating margin, cash flow statement, and the one-off items behind fourth-quarter owner net income.

  3. Around May 2027 (estimated)

    Q1 2027 results. This is the point to check whether quarterly operating profit stays positive and whether the decline in owner net income continues.

  4. During 2027 (timing not confirmed)

    Phase 3 results for the diabetes drug JY303, progress on the combination product, and the approval outcome for JY304. These show when and how much new products could contribute to sales.

12

Overall view

JIN Yang Pharmaceutical is an ETC-focused drugmaker whose revenue rose for three consecutive years to KRW 120.7 billion in 2025. Operating profit, however, fell from KRW 11.7 billion in 2024 to KRW 2.53 billion in 2025, and the operating margin dropped to 2.1%.

Quarterly operating profit was positive in every quarter of 2026 so far, and third-quarter revenue rose 11.5% year on year.

Owner net income peaked at KRW 19.3 billion in the fourth quarter of 2025 and has declined since, so how much of the KRW 25 billion over the last four quarters depends on one-off items needs to be confirmed.

Positive factors include a prescription base spread across circulatory, gastrointestinal and central nervous system products, a lower debt ratio, and an improved-drug pipeline. Negative factors include the 2025 earnings slump, generic competition in the core product, and lower operating cash flow in 2025.

On valuation, total equity exceeds market capitalization, so asset-based comparison is possible, but interpretations diverge until earnings stabilize. The next checkpoint is the operating margin and the quarterly trend of owner net income in the 2026 annual business report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. dailymedi.com
  2. m.finance.daum.net
  3. etoday.co.kr
  4. medipana.com
  5. dailyinvest.kr
  6. hkn24.com
  7. dementianews.co.kr
  8. app.rndcircle.io
  9. businesspost.co.kr
  10. medipana.com
  11. news.nate.com
  12. investing.com
  13. incruit.com
  14. bbn.kiwoom.com
  15. judal.co.kr
  16. judal.co.kr
  17. jobkorea.co.kr
  18. markets.hankyung.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis